List of Excipients in Branded Drug TICOVAC

TICOVAC Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

TICOVAC is a preservative-free, aluminum-adjuvanted, inactivated tick-borne encephalitis vaccine marketed by Pfizer in the United States. Its excipient platform is commercially conservative: aluminum hydroxide supports immunogenicity, while human serum albumin, sodium chloride, trometamol, and water for injection support formulation stability and isotonicity. The strongest opportunities are in adjuvant optimization, prefilled-device development, pediatric dose efficiency, cold-chain resilience, and regional supply partnerships rather than direct substitution of the approved product.

What excipients are used in TICOVAC?

TICOVAC contains a limited excipient system designed for intramuscular administration and refrigerated storage.

Component	Function	Commercial relevance
Aluminum hydroxide	Adsorbed adjuvant that enhances immune response	Primary platform for differentiated adjuvant or antigen-loading strategies
Human serum albumin	Stabilizer and protein protectant	Creates sourcing, safety, and animal-origin-free substitution opportunities
Sodium chloride	Tonicity adjustment	Low differentiation; important for injection tolerability
Trometamol	Buffering agent	Supports pH control and antigen stability
Water for injection	Vehicle	Standard parenteral excipient
Residual process materials	May include manufacturing-process residues such as formaldehyde, antibiotics, or culture-related components	Relevant to labeling, allergy management, and alternative manufacturing processes

The exact qualitative and quantitative composition depends on the jurisdictional product information. The U.S. prescribing information identifies aluminum hydroxide, human serum albumin, sodium chloride, trometamol, and water for injection among the product components.[1]

TICOVAC does not contain thimerosal as a preservative. It is supplied as a single-dose injectable product, reducing the commercial need for antimicrobial preservatives but increasing packaging and device costs.

How does the TICOVAC formulation work?

TICOVAC uses an inactivated tick-borne encephalitis virus antigen adsorbed to aluminum hydroxide. The aluminum adjuvant is the central functional excipient because it helps create a depot-like antigen presentation environment and promotes innate immune activation.

Human serum albumin provides protein stabilization during manufacturing, storage, and temperature variation. Trometamol provides buffering capacity, while sodium chloride supports an injectable formulation compatible with intramuscular administration.

The formulation strategy has three commercial characteristics:

1. It uses established excipients with broad parenteral regulatory precedent.
2. It avoids the complexity of newer proprietary adjuvant systems.
3. It remains dependent on cold-chain distribution at 2°C to 8°C.

The principal technical constraint is that inactivated viral antigens can be sensitive to adsorption, aggregation, surface interactions, and temperature excursions. An excipient change that appears chemically minor may alter antigen recovery, particle size, potency, immune response, or syringeability.

What is the FDA regulatory status of TICOVAC?

TICOVAC is FDA-approved for active immunization against tick-borne encephalitis in individuals 1 year of age and older who reside in or travel to areas where tick-borne encephalitis virus is prevalent and who are at increased risk of exposure.[1]

Regulatory item	Status
Product	TICOVAC
Manufacturer in U.S. labeling	Pfizer
Active ingredient	Inactivated tick-borne encephalitis virus
Dosage form	Intramuscular injectable suspension
U.S. approval	FDA approval in 2021
Age range	Adults and children 1 year and older
Storage	Refrigerated, generally 2°C to 8°C
Preservative	No thimerosal preservative
Regulatory category	Biological vaccine, not a conventional small-molecule drug

The U.S. product is associated with the European FSME-IMMUN product family, which has a longer history of use in endemic markets. FDA approval relied on immunogenicity and bridging data because tick-borne encephalitis is not endemic in the continental United States at the same scale as in parts of Europe.[1,2]

What excipient patents protect TICOVAC?

Public product information identifies the formulation components but does not establish that the individual excipients are protected by enforceable, product-specific patents. Aluminum hydroxide, human serum albumin, sodium chloride, trometamol, and water for injection are longstanding materials with extensive prior art and broad regulatory use.

The likely protection profile is concentrated in the following categories:

• Inactivated tick-borne encephalitis virus antigen preparation
• Virus strain selection and propagation
• Purification and inactivation processes
• Antigen adsorption to aluminum hydroxide
• Stability and potency-control methods
• Manufacturing processes
• Combination or dosing regimens
• Packaging and delivery systems

The FDA Orange Book is generally not the principal patent-disclosure source for vaccines because biologic products are regulated through biologics licensing pathways rather than conventional drug applications. TICOVAC’s relevant intellectual-property analysis therefore requires review of biologic patent families, FDA reference-product records, European patent databases, national registers, and litigation databases.

No reliable commercial conclusion should be drawn from the absence of an Orange Book entry. A vaccine can have meaningful formulation, process, manufacturing, or method-of-use protection without an Orange Book listing.

How strong is the TICOVAC excipient patent estate?

The excipient estate appears stronger as a formulation and manufacturing platform than as a composition-of-matter estate for the individual excipients.

IP category	Expected strength	Reason
Aluminum hydroxide as a standalone excipient	Low	Mature, widely used material with extensive prior art
Human serum albumin as a stabilizer	Low to moderate	Established use, but specific concentration and process combinations may be protectable
Specific antigen-adjuvant adsorption conditions	Moderate	May provide narrower protection tied to potency, particle characteristics, or immune response
Viral inactivation and purification	Moderate to strong	Process parameters can be difficult to replicate while maintaining potency
Strain and antigen production	Stronger	Product-specific biological material and manufacturing know-how can create barriers
Container closure and prefilled delivery	Moderate	Device and packaging claims may support incremental exclusivity
Cold-chain stabilization	Moderate	Temperature-excursion and lyophilization technologies can be differentiated

For a competing manufacturer, replacing aluminum hydroxide with another adjuvant could avoid some formulation claims but create a new clinical and regulatory package. Replacing human serum albumin with recombinant albumin, polysorbate, sucrose, amino acids, or another stabilizer may reduce animal-origin concerns, but the revised product would require comparability, stability, and immunogenicity evidence.

What formulation opportunities exist for TICOVAC?

Recombinant human albumin substitution

Human serum albumin is a logical target for excipient innovation. Recombinant human albumin could offer:

• Reduced dependence on plasma-derived supply
• More consistent lot characteristics
• Lower exposure to human-origin raw materials
• A stronger animal-origin-free manufacturing position
• Potentially simplified procurement in some jurisdictions

The commercial challenge is proof of equivalence. Albumin is not merely a bulking agent. It can influence adsorption, aggregation, surface protection, and antigen recovery. A substitute must preserve potency and stability across the full shelf life.

Aluminum hydroxide optimization

Aluminum hydroxide remains the most credible near-term platform for an improved TICOVAC-like product. Opportunities include:

• Controlled particle size and surface area
• More consistent antigen loading
• Reduced sedimentation
• Improved resuspendability
• Lower injection-site reactogenicity
• Higher antigen dose efficiency
• Better compatibility with prefilled syringes

An improved aluminum hydroxide system could support a lower-volume pediatric presentation or reduce the amount of antigen required per dose. Such claims may be protectable if linked to measurable product attributes and clinical or immunological performance.

Alternative adjuvants

Alternative systems such as oil-in-water emulsions, toll-like receptor agonists, saponin-based adjuvants, or liposomal systems could increase immune response or reduce antigen dose. They also create higher regulatory risk.

A new adjuvant would likely require:

• New toxicology data
• Broader clinical development
• More extensive characterization
• Greater manufacturing complexity
• New global regulatory discussions
• Potentially different reactogenicity labeling

The opportunity is stronger for a next-generation vaccine than for a simple generic or biosimilar-style substitution.

Buffer and stabilizer redesign

Trometamol and sodium chloride have limited standalone commercial differentiation. A redesign using histidine, phosphate, citrate, sucrose, trehalose, amino acids, or recombinant albumin could improve stability, but the value would depend on a measurable benefit such as:

• Longer shelf life
• Reduced cold-chain sensitivity
• Faster recovery after temperature excursions
• Reduced adsorption loss
• Lower aggregate formation
• Improved syringeability

A buffer change without a clear product-performance advantage is unlikely to justify a premium.

What commercial opportunities exist in TICOVAC packaging and delivery?

The approved presentation creates opportunities in device engineering rather than only in excipient supply.

Prefilled syringes

A prefilled syringe can reduce preparation steps, medication errors, and wastage. The main technical issues are aluminum hydroxide suspension behavior, silicon oil exposure, stopper compatibility, and resuspension before injection.

A successful prefilled presentation would need validated dose uniformity after storage, transport, and handling. Device patents could protect syringe geometry, agitation instructions, suspension-control features, or integrated needle safety systems.

Pediatric dose presentation

TICOVAC is used in children from 1 year of age. A pediatric presentation can improve usability through:

• Lower fill volume
• Child-specific syringe markings
• Reduced dead volume
• Easier resuspension
• Integrated needle protection
• Clinic-oriented multi-pack configurations

The commercial value is highest in travel medicine, occupational health, pediatric infectious-disease clinics, and national vaccination programs.

Temperature-excursion protection

TICOVAC requires refrigerated storage. Excipients and packaging that preserve antigen potency during short temperature excursions could reduce distribution losses and expand use in markets with weaker cold-chain infrastructure.

Commercial options include:

• Stabilizing excipient combinations
• Improved secondary packaging
• Temperature indicators
• Validated insulated transport systems
• Freeze-protection packaging
• Expanded stability data supporting controlled excursions

A true room-temperature presentation would be commercially significant but technically difficult. Freeze sensitivity is also important because accidental freezing can damage adsorbed vaccine suspensions.

When does TICOVAC lose exclusivity?

TICOVAC does not have a single publicly determinative small-molecule patent-expiration date comparable to a conventional drug listed in the Orange Book. Biologic and vaccine exclusivity must be assessed across regulatory exclusivity, patent families, manufacturing know-how, process claims, and country-specific rights.

The practical entry timeline depends on:

• Patent expiry for the relevant antigen and process claims
• Data or reference-product exclusivity in each jurisdiction
• Availability of a licensed manufacturing process
• Clinical requirements for an alternative vaccine
• WHO and national tender qualification
• Supply of viral seed, cell substrates, and adjuvant components
• Product-specific immunogenicity requirements

For a conventional competitor, loss of one formulation patent would not necessarily create immediate market entry. Manufacturing consistency and regulatory comparability can remain the principal barriers.

Are generic or biosimilar challenges likely for TICOVAC?

A conventional generic pathway is unlikely because TICOVAC is a biological vaccine rather than a small-molecule drug. A competing product would more likely require an independent biologics license, a biosimilar-like strategy where legally available, or a full vaccine development program.

The main entry scenarios are:

Scenario	Regulatory burden	Commercial timing	Risk to TICOVAC
Same antigen, similar aluminum formulation	Moderate to high	Medium term	Moderate
Alternative strain or manufacturing process	High	Longer term	Moderate
Novel adjuvant formulation	High	Long term	High if clinically superior
Localized manufacturing in endemic country	Variable	Medium term	High in tenders
Reformulated prefilled product	Moderate to high	Medium term	Low to moderate
Recombinant-albumin replacement	Moderate	Medium term	Low unless stability improves

A Paragraph IV challenge is not the normal framework for a vaccine biologic. Competitors would need to evaluate patent invalidity, non-infringement, and regulatory pathways outside the classic Hatch-Waxman model.

Which companies could challenge or compete with TICOVAC?

Competition is more likely to come from established tick-borne encephalitis vaccine manufacturers than from generic-drug companies.

Relevant competing product families include:

• Pfizer’s TICOVAC and FSME-IMMUN
• Bavarian Nordic’s TBE vaccine products in selected markets
• Encepur products associated with Bavarian Nordic’s portfolio
• Regional vaccine manufacturers serving Austria, Germany, Central Europe, Russia, and parts of Asia

The competitive landscape is geographically fragmented. Product availability, national procurement, travel-vaccine recommendations, and endemic-area vaccination programs influence market share more than U.S. retail pharmacy competition.

Potential commercial entrants include:

• Contract manufacturers with aluminum-adjuvant capability
• Regional biologics manufacturers
• Vaccine companies with recombinant albumin supply
• Device companies developing suspension-compatible prefilled syringes
• Cold-chain and packaging companies
• Public-sector manufacturers targeting endemic markets

What licensing and partnership opportunities exist?

The most actionable licensing opportunities are platform-based.

Excipient and adjuvant licensing

A supplier with a validated aluminum hydroxide platform could license:

• Controlled morphology aluminum hydroxide
• High-loading antigen adsorption
• Low-reactogenicity adjuvant systems
• Recombinant human albumin
• Freeze-protection stabilizers
• Temperature-excursion formulations

The strongest deal structure would connect the excipient to a defined performance claim, such as longer stability, lower antigen dose, or improved suspension behavior.

Manufacturing partnerships

TICOVAC-like products require specialized viral vaccine manufacturing. Partnership opportunities include:

• Regional fill-finish
• Local production under technology transfer
• National stockpile supply
• Contract testing and potency release
• Seed-virus and antigen-process licensing
• Dual-source raw-material agreements

Technology transfer is more valuable when it includes analytical methods, adsorption controls, inactivation validation, and process-specific know-how.

Device partnerships

A prefilled syringe or auto-disable presentation could support licensing to public-health programs. Device integration must account for particulate suspension, dose uniformity, needle gauge, and storage stability.

What revenue exposure does TICOVAC create?

TICOVAC revenue is exposed to travel vaccination, endemic-area immunization, occupational exposure, military use, and government procurement. The product’s commercial base is broader in Europe than in the United States because tick-borne encephalitis is endemic in parts of Central, Northern, and Eastern Europe.

Revenue drivers include:

• Incidence and geographic expansion of tick-borne encephalitis
• Travel to endemic regions
• National vaccination recommendations
• Government tenders
• Vaccine availability and supply continuity
• Booster compliance
• Pediatric vaccination programs
• Climate-driven changes in tick distribution and seasonal activity

The principal commercial risk is episodic demand. Travel vaccination can rise rapidly during periods of increased public awareness but may be less predictable than routine childhood immunization.

What geographic coverage matters for TICOVAC excipient commercialization?

A formulation or excipient partner should assess at least four regulatory regions:

Region	Main commercial issue
United States	FDA biologics requirements and limited endemic-market demand
European Union	National vaccination programs, centralized or decentralized regulatory considerations, and established TBE use
Central and Eastern Europe	Government tenders and high endemic exposure
Asia-Pacific	Local epidemiology, national registration, and manufacturing localization

Animal-origin-free excipients may have stronger value in Europe and certain Asian markets where procurement specifications, cultural requirements, or supply-chain controls favor recombinant or synthetic components.

Key Takeaways

• TICOVAC uses aluminum hydroxide, human serum albumin, sodium chloride, trometamol, and water for injection in a preservative-free injectable formulation.
• Aluminum hydroxide is the primary excipient opportunity because it affects immune response, antigen loading, suspension behavior, and reactogenicity.
• Recombinant human albumin is the clearest substitution opportunity, subject to stability and immunogenicity comparability.
• The most defensible IP is likely to reside in antigen production, inactivation, purification, adsorption conditions, stability, and manufacturing methods rather than in standalone excipient composition.
• TICOVAC does not follow a conventional Orange Book or Paragraph IV exclusivity model.
• Commercial competition is likely to come from regional vaccine manufacturers and established TBE vaccine suppliers, not conventional generic-drug companies.
• Prefilled syringes, pediatric dose optimization, freeze protection, and temperature-excursion stability offer practical product-development opportunities.
• The highest-value licensing targets are excipient platforms linked to measurable performance improvements and manufacturing technology-transfer packages.

FAQs

Is TICOVAC preservative-free?

Yes. U.S. product information does not identify thimerosal as a preservative in TICOVAC. The product is supplied as a single-dose intramuscular vaccine.[1]

Does TICOVAC contain aluminum?

Yes. Aluminum hydroxide is used as the adjuvant. The U.S. label identifies approximately 0.35 mg of aluminum hydroxide per 0.5 mL adult dose.[1]

Can human serum albumin be removed from TICOVAC?

It could potentially be replaced, but the substitute would need to preserve antigen stability, adsorption behavior, potency, and shelf life. Recombinant human albumin is the most commercially logical replacement candidate.

Is TICOVAC a biosimilar?

No. TICOVAC is an inactivated viral vaccine. A competing product would face vaccine-specific biologics requirements and would not ordinarily enter through a conventional generic-drug application.

What is the best excipient opportunity for a TICOVAC competitor?

The strongest near-term opportunity is a validated aluminum hydroxide and stabilizer system that improves antigen loading, suspension uniformity, temperature tolerance, or pediatric dose efficiency without requiring a wholly new adjuvant platform.

References

1. U.S. Food and Drug Administration. (2021). TICOVAC: Prescribing information. Pfizer Inc.

2. European Medicines Agency. (2024). FSME-IMMUN product information. European Medicines Agency.

3. Centers for Disease Control and Prevention. (2024). Tick-borne encephalitis vaccine information and travel health guidance. U.S. Department of Health and Human Services.

4. World Health Organization. (2011). Vaccines against tick-borne encephalitis: WHO position paper. Weekly Epidemiological Record, 86(38), 373-384.

5. Pfizer Inc. (2024). TICOVAC product information and healthcare professional materials. Pfizer Inc.